In this work we studied the in vitro toxicity of ± 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-dichlorophenoxy]quinoline (DN3-27-1) against stationary phase promastigotes Leishmania (L.) mexicana. Our results indicate that this drug induces an important reduction in parasite growth and killing compared to the reference drug N-methyl meglumine (Glucantime™). DN3-27-1 was not toxic to Hela cells cultured in vitro. This is the first report describing the promising potential of DN3-27-1 in treatment of L. (L.) mexicana infections.
RobertsLJ, HandmanE, FooteSJ. (2005) Science, medicine, and the future: Leishmaniasis. British Medical Journal, 321, 801–804.
4.
Lezama-DávilaCM, Isaac-MárquezAP, SatoskarAR. (2007) Immunoregulation of chiclero's ulcer. In: TerrazasLI. ed. Advances in the immunobiology of parasitic diseases. India: Research Signpost, 237–252.
5.
Lezama-DávilaCM, Isaac-MárquezAP. (2006) Systemic cytokine response in humans with chiclero's ulcers. Parasitology Research, 99, 546–553.
6.
Isaac-MárquezAP, Lezama-DávilaCM. (2003) Detection of pathogenic bacteria in skin lesions of patients with chiclero's ulcer. Reluctant response to antimonial treatment. Memórias do Instituto Oswaldo Cruz, 98, 1093–1095.
WerbovetzKA. (2002) Promising therapeutic targets for antileishmanial drugs. Expert Opinion on TherapeuticTargets, 6, 407–422.
9.
CroftSL, SundarS, FairlambAH. (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews, 19, 111–126.
10.
GourbalB, SonucN, BhattacharjeeH, LegareD, SundarS, OuelletteM, RosenBP, MukhopadhyayR. (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. Journal of Biological Chemistry, 279, 31010–31017.
11.
RojasR, ValderramaL, ValderramaM, VaronaMX, OuelletteM, SaraviaNG. (2006) Resistance to antimony and treatment failure in human Leishmania (Viana) infection. Journal of Infectious Diseases, 193, 1375–1383.
NanayakkaraNP, AgerALJr, BartlettMS, YardleyV, CroftSL, KhanIA, McChesneyJD, WalkerLA. (2008) Antiparasitic activities and toxicities of individual enantiomers of the 8-Aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrobial Agents and Chemotherapy, 52, 2130–2137.
17.
BermanJD, LeeLS. (1983) Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. American Journal of Tropical Medicine and Hygiene, 32, 753–759.
18.
KinnamonKE, SteckEA, LoizeauxPS, HansonWL, ChapmanWLJr, WaitsVB. (1978) The antileishmanial activity of lepidines. American Journal of Tropical Medicine and Hygiene, 27, 751–757.
19.
VennerstromJL, LovelaceJK, WaitsVB, HansonWL, KlaymanDL. (1990) Berberine derivatives as antileishmanial drugs. Antimicrobial Agents and Chemotherapy, 34, 918–921.
20.
TekwaniBL, WalkerLA. (2006) 8-Aminoquinolines: future role as antiprotozoal drugs. Current Opinion in Infectious Diseases, 19, 623–631.
21.
McChesneyJD, NanayakkaraNP, BartlettM, AgerAL. (2002) 8-Aminoquinolines. U.S. patent 6,376,511.
